BCL2 and lymphoma: Adding Ibrutinib to R-CHOP neutralized the inferior EFS and OS outcome in younger patients with high co-expression of MYC and BCL2 (slightly differently defined from the more commonly used double-expressor lymphoma status; see above) [77].